ESR1 and breast cancer: In addition, the randomized coopERA breast cancer trial (NCT04436744) included a 2-week WOO phase that compared giredestrant 30 mg with anastrozole 1 mg in postmenopausal women with ER + /HER2− breast cancer [15].